



Universiteit
Leiden
The Netherlands

On cerebral lupus: from pathogenesis to clinical outcomes

Magro Checa, C.

Citation

Magro Checa, C. (2019, May 9). *On cerebral lupus: from pathogenesis to clinical outcomes*. Retrieved from <https://hdl.handle.net/1887/72199>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/72199>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:

<http://hdl.handle.net/1887/72199>

Author: Magro-Checa, C.

Title: On cerebral lupus: from pathogenesis to clinical outcomes

Issue Date: 2019-05-09

5

ARE SERUM AUTOANTIBODIES ASSOCIATED WITH BRAIN CHANGES IN SYSTEMIC LUPUS ERYTHEMATOSUS? – MRI DATA FROM THE LEIDEN NP-SLE COHORT

César Magro-Checa, Sumeet Kumar, Sofia Ramiro,
Liesbeth J. Beaart-van de Voorde, Jeroen Eikenboom,
Itamar Ronen, Jeroen de Bresser, Mark A. van Buchem,
Tom W. Huizinga, Gerda M. Steup-Beekman

ABSTRACT

Objective: The effect of serum autoantibodies on the brain of systemic lupus erythematosus (SLE) patients remains unclear. We investigated whether serum autoantibodies, individually and assessed in groups, are associated with specific brain-MRI abnormalities or whether these structural changes are associated with other SLE-related or traditional cardiovascular disease risk factors.

Methods: All patients underwent brain 3Tesla-MRI. White matter hyperintensities (WMHs), ischemic lesions, inflammatory-like lesions and cerebral atrophy were scored. Serum autoantibodies analyzed included lupus anticoagulant (LAC), anticardiolipine (aCL) IgG and IgM (first 3 also grouped into antiphospholipid autoantibodies (aPL)), anti-dsDNA, anti-SSA, anti-SSB, anti-RNP, and anti-Sm (the latter 5 grouped into SLE-related autoantibodies). Associations were assessed using logistic regression analysis adjusted for potential confounders. Furthermore, a sensitivity analysis including anti-Beta2 glycoprotein-1 antibodies (anti- β 2GP1) in the aPL group was performed and the potential modification role of the neuropsychiatric clinical status in the model was assessed.

Results: 325 patients (mean age 42 years (SD 14), 89% female) were included. The following MRI-brain abnormalities were found: WMHs (71%), lacunar infarcts (21%), gliosis (11%), micro-hemorrhages (5%), large hemorrhages (2%), inflammatory-like lesions (6%) and atrophy (14%). No associations were found between individual or total SLE-related autoantibodies and inflammatory-like lesions. A higher number of positive aPL was associated with lacunar infarcts (OR 1.37 (95%CI 1.02-1.99) and gliosis (OR 2.15 (1.37-3.37)). LAC was associated with lacunar infarcts in white matter (OR 3.38 (1.32-8.68)) and atrophy (OR 2.49 (1.01-6.15)), and aCL IgG with gliosis (OR 2.71 (1.05-7.02)). Among other variables, SLE patients with hypertension presented a higher chance for WMHs (OR 5.61 (2.52-12.48)) and lacunar infarcts in WM (OR 2.52 (1.10-5.74)) and basal ganglia (OR 8.34 (2.19-31.70)), while cumulative SLE-damage was correlated with lacunar infarcts in WM (OR 1.43 (1.07-1.90)), basal ganglia (OR 1.72 (1.18-2.51)) and cerebellum (OR 1.79 (1.33-2.41)). These associations were confirmed in the sensitivity analysis.

Conclusions: Brain abnormalities in SLE represent different underlying pathogenic mechanisms. aPL are associated with ischemic brain changes in SLE, while the presence of SLE-related serum autoantibodies is not related to inflammatory-like lesions. Hypertension and cumulative SLE-damage associate with ischemic MRI-brain changes in SLE, suggesting the importance of accelerated atherosclerosis in this process.

Nervous system involvement in systemic lupus erythematosus (SLE) leads to a heterogeneous group of neuropsychiatric (NP) manifestations. The two main underlying pathophysiologic processes in the brain resulting in NP-SLE are thought to be inflammation and ischemia.(1,2) The mechanisms that ultimately result in these pathophysiological changes and how they are related to each other remain poorly understood.

Over the past decade the type I interferon (IFN) was postulated to play a central role in SLE pathogenesis by promoting feedback loops progressively disrupting the peripheral immune tolerance and driving disease activity.(3) Recent discoveries implicate IFN-alpha together with the classical complement cascade as major pathways used by microglia for synaptic pruning in mice. Chronic peripheral inflammation in SLE may play a role in the aberrant activation of microglia and subsequently stimulate synapse loss, tagging inappropriate synaptic connections between neurons and subsequently leading to cerebral dysfunction.(4,5) The elevation of IFN-alpha activity has been related to autoantibody accumulation.(6) Moreover, several studies have described that autoantibody-containing immune-complexes may drive type I IFN activation.(7-9) Autoantibodies may also exert a direct effect upon neurons. The disruption of the blood brain barrier (BBB) integrity may permit the influx of neuropathic antibodies which may target synapses for engulfment by microglia.(10) Previous studies suggested that anti-dsDNA antibodies cross-react with N-methyl-D-aspartate (NMDA) receptors, and injecting these antibodies into mice causes hippocampal neuronal loss and cognitive impairment only when the BBB has been disrupted.(11,12)

Autoantibodies have also been associated with an ischemic pathogenic process. Antiphospholipid antibodies (aPL), especially lupus anticoagulant (LAC), have been related to intracranial thrombosis.(13) The complement cascade in close relation to aPL also plays a role in microvascular injury and NP-SLE pathogenesis.(14-16) Furthermore, accelerated atherosclerosis and traditional cardiovascular disease (CVD) risk factors have been involved in the ischemic process in SLE.(17)

Despite the fact that imaging abnormalities are not specific for NP-SLE, Magnetic Resonance Imaging (MRI) remains the neuroimaging technique of choice due to its superior soft tissue resolution. In a paired neuroimaging-autopsy study, Sibbit and coworkers observed that brain lesions in NP-SLE detected by MRI represent underlying cerebrovascular and parenchymal brain injury on histopathology.(18) Cerebral abnormalities that have been described in SLE on MRI are diverse; the most commonly reported is small vessel disease, especially white matter hyperintensities (WMHs) and lacunar infarcts, but also large vessel disease, inflammatory-like lesions (i.e. multifocal grey matter lesions) and brain atrophy are described.(19-23) While a fair number of studies on MRI abnormalities in SLE and NP-SLE have been published, only a few studies tried to unravel the mechanisms leading to these changes. It has been

proposed that focal lesions in SLE represent neuronal injury from various etiologies, ischemia and inflammation being the most important.(18) Luyendijk and coworkers described several distinct brain-MRI patterns in NP-SLE patients that were suggestive of different underlying pathogenic mechanisms.(24) The understanding of the pathogenic mechanisms leading to MRI abnormalities in SLE may be important to develop a rational prevention and treatment approach and in categorization of patients in further research.(23,24)

Based upon this knowledge, our primary hypothesis was that the total number of SLE-related autoantibodies is associated with inflammatory-like lesions and the number of aPL autoantibodies with ischemic changes as seen on brain-MRI. As a secondary objective we analyzed if MRI abnormalities were directly related to individual autoantibodies or otherwise with other SLE-related or CVD risk factors. Overall, we aim to investigate whether the underlying immune abnormalities in SLE are associated with pathophysiological changes as seen on brain-MRI.

METHODS

Study population

Between September 2007 and February 2016 a total of 325 SLE patients were seen in the Leiden NP-SLE-clinic and included in the present study. All patients fulfilled the ACR 1982 revised criteria for SLE.(25,26) Our hospital is a tertiary referral centre serving as a national referral centre for NP-SLE in the Netherlands. Patients are sent by a referral rheumatologist or other medical specialist to our center when SLE patients present NP manifestations. Therefore, all patients included in this study presented NP manifestations at time of the MRI. They were admitted for a 1-day period to the Leiden University Medical Center (LUMC). All patients underwent standardized multidisciplinary medical examination and extensive neuropsychological testing, serologic assessment and brain-MRI. Evaluations included in the multidisciplinary assessment have been reported in detail before.(27) The attribution process of NP-events to SLE and one of its underlying pathogenic mechanisms (ischemic or inflammatory) or to other etiologies was decided after multidisciplinary consensus and confirmed after re-assessment of patients at follow-up as described elsewhere.(28) This study was approved by the local medical ethics committee and all patients provided written informed consent.

MRI protocol and scoring

All subjects underwent a 3-Tesla MRI in the same scanner according to a standardized protocol (Achieva; Philips Healthcare). The scanning protocol included high-resolution T1-weighted, T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, followed

by a T1-weighted sequence obtained after intravenous administration of gadolinium contrast agent. Scan parameters are shown in the **Supplementary Table 1**. All MRI examinations were visually examined by an experienced neuroradiologist (S. K.) who was blinded to clinical information. Areas of abnormalities were identified and their locations were documented. Deep WMHs were rated according to the visual Fazekas rating scale (ranging 0-3) on FLAIR images.(29) For analysis, we dichotomized this variable into low (Fazekas score <2) and high presence of WMHs (Fazekas score \geq 2). The presence or absence of lacunar infarcts, large vessel infarcts, dural sinus thrombosis, cerebral micro-bleeds (CMBs), large hemorrhages, gliosis and inflammatory-like changes was also assessed. Lacunar infarcts were defined as ovoid areas of T2 hyperintense signal, with a hyperintense rim on FLAIR, measuring less than 20mm. These were distinguished from WMHs on the basis of central low signal on FLAIR. Lacunar infarcts were assessed in the white matter (WM), basal ganglia, thalamus, brainstem and cerebellum. Large vessel infarcts were defined as areas of T2/FLAIR hyperintensity involving the cortex and underlying WM confined to the distribution of a vascular territory. If these areas were restricted in diffusion, then the infarct was labeled acute. CMBs were defined as small (2-5mm), homogeneous and round areas of susceptibility artefacts on gradient echo images.(30) Gliosis was defined as a focal area of volume loss accompanied by T2 and FLAIR hyperintensity. If the area of gliosis was accompanied by hemosiderosis, it was deemed to have been the result of a previous hemorrhage. Presence of dural venous sinus thrombosis was suggested by the loss of normal flow voids in a dural venous sinus and absence of contrast enhancement within it and was confirmed by a MR Venogram showing loss of the corresponding normal flow signal. Lesions showing post-contrast enhancement following intravenous gadolinium injection, cortical hyperintensity and/or swelling on FLAIR or gyral restricted diffusion were thought to be inflammatory-type lesions according to Luyendijk *et al.*(24) Cerebral atrophy was assessed using the Pasquier scale, a four-point rating scale to assess cerebral atrophy ranging from 0 (absent) to 3 (severe cortical atrophy) and computed into low (Pasquier scale <2) and high (Pasquier scale \geq 2).(31) See **Supplementary Figures 1-3** in additional supporting material.

Autoantibodies

Blood samples of all patients were collected from each participant at 08:00 a.m.. Determinations of serum anti-double-stranded DNA (anti-dsDNA), anti-Sm, anti-RNP, anti-SSA/Ro52, anti-SSB/La and aPL including anticardiolipin (aCL), anti-Beta2 glycoprotein 1 antibodies (anti- β 2GP1) and LAC were performed the same day of the blood extraction in the routine clinical laboratory. IgG anti-dsDNA antibodies were detected using the Crithidia luciliae indirect immune fluorescence technique (Immuno Concepts, Sacramento, CA, USA). IgG antibodies against SS-A/Ro-52, SS-B/La, Sm, RNP and IgG and IgM aCL and anti- β 2GP1 were determined using a Phadia 250 EliA fluorescence enzyme immunoassay

(FEIA) (Thermo Scientific, Freiburg, Germany). LAC was determined using STA-Rack and STA Evolution coagulation analyzers (Stago, Parsippany, NJ, USA).

Complement levels

Levels of C3 and C4 in serum were measured using laser nephelometry. Based on the normal limits for our laboratory, C3 <0.9g/l and C4 <95mg/l were defined as low.

SLE-related activity and damage

SLE disease activity was assessed with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K).³² Permanent and irreversible damage due to SLE was calculated with the systemic lupus international collaborating clinics (SLICC)/American College of Rheumatology damage index (SDI).³³ All SLEDAI-2K and SDI values were calculated without NP variables. SDI was calculated without the diabetes variable.

Cardiovascular variables

At inclusion, data on age, gender, duration of SLE, medical history and CVD risk factors (smoking, hypertension, diabetes, dyslipidemia, body mass index (BMI)) were recorded, through interviewing the patient and by studying medical records. Furthermore, at this point glucose, triglycerides, total cholesterol, low-density (LDLc) and high-density lipoproteins cholesterol concentrations (HDLc) were determined. Hypertension was defined as elevated blood pressure >140/90mmHg or receiving antihypertensive therapy. Dyslipidemia was defined according to the National Cholesterol Education Program (Total cholesterol >5.2mmol/L, triglycerides >1.7mmol/L, LDLc >3.4mmol/L and HDLc <1mmol/L for men and <1.3mmol for women) or receiving dyslipidemia therapy.³⁴ Cigarette smoking was divided into current and ever smoking. Diabetes was defined as a fasting plasma glucose >7.0mmol/liter or receiving current anti-diabetic therapy. BMI was used as a continuous variable.

Statistical analysis

Demographic and clinical parameters were described as mean and standard deviations (SD) or proportions, as appropriate. The relationship between autoantibodies and MRI abnormalities was investigated through means of logistic regression analyses through which odds ratio (OR) and 95% confidence intervals (95% CI) were calculated. First, an analysis of interaction between each of the autoantibodies (in groups and individually) and the diagnosis (NP-SLE vs SLE without NP-SLE) on the different outcomes was conducted. If interactions were statistically significant ($p < 0.1$), analyses were stratified in both subgroups. If differences in the relationships (between autoantibodies and MRI abnormalities) were considered clinically relevant, all analyses were further stratified for NP-SLE diagnosis. Subsequently, analyses were conducted with groups of autoantibodies including the number of positive aPL

(LAC, aCL IgG and IgM) ranging from 0-3 and the number of positive SLE-related antibodies (anti-dsDNA, anti-Sm, anti-RNP, anti-SSA/Ro52, anti-SSB/La) ranging from 0-5. Afterwards all these antibodies were included individually in separate models. Univariable regression was followed by multivariable regression. Variables from the univariable analysis with a $p < 0.20$ were included in the multivariable model. Some variables known from the literature as potential confounders were forced into the models to test whether they confounded the main relationships of interest. Significant variables or variables with a confounding effect on the relationship between autoantibodies and MRI abnormalities were kept in the final models. Because anti- β 2GP1 (IgG and IgM) were not tested in all patients, a sensitivity analysis was performed including these autoantibodies in the model as covariates first added in the aPL group (LAC, aCL IgG and IgM, anti- β 2GP1 IgG and IgM) ranging 0-5 and later analyzed individually. A $p < 0.05$ was used as level of significance. Statistical analysis was performed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Three hundred twenty-five participants underwent brain-MRI scan. **Table 1** shows the clinical characteristics, autoantibody profile, CVD risk and SLE-related factors in the study population.

Brain-MRI abnormalities in SLE

Brain abnormalities in all SLE patients included in our cohort are shown in **Table 2**. WMHs were the most frequent radiologic finding with at least one WMH observed in 229 SLE patients (70.5%). Of all 325 patients, 61 (18.8%) had a Fazekas score of ≥ 2 . A total of 118 lacunar infarcts in 68 SLE patients were found. Cerebral atrophy (Pasquier ≥ 2) was found in 44 (13.6%) patients. A description of brain-MRI abnormalities according to the attribution of NP-events into the different clinical subgroups (non-NP-SLE, ischemic and inflammatory NP-SLE) is given in **Supplementary Table 2**.

Table 1. Clinical characteristics of the 325 SLE included patients

	n (%) or mean (SD)
Antibodies	
aCL IgG	63 (19.4%)
aCL IgM	31 (9.5%)
LAC	99 (30.5%)
Anti- β 2GP1 IgG [†]	40 (14.4%)
Anti- β 2GP1 IgM [†]	12 (4.3%)
ANA	315 (96.9%)
ENA	181 (55.7%)
Anti-ds-DNA	160 (49.2%)
Anti-SSA/Ro52	134 (41.2%)
Anti-SSB/La	43 (13.2%)
Anti-RNP	62 (19.1%)
Anti-Sm	41 (12.6%)
SLE-related factors	
SLEDAI-2K	5.1 (5.1)
SDI	1.2 (1.3)
C3 low	104 (32%)
C4 low	85 (26.2%)
Cardiovascular risk factors	
Hypertension	130 (40%)
Smoking	
Current smoker	86 (26.5%)
Ever smoker	160 (49.2%)
Never smoker	165 (50.8%)
BMI (kg/m ²)	24 (21-28)
Dyslipidemia	186 (57.2%)
Diabetes mellitus	19 (5.8%)
Attribution of NP events	
Non-NP-SLE	204 (62.8%)
Ischemic NP-SLE	43 (13.2%)
Inflammatory NP-SLE	78 (24%)

aCL: anticardiolipin; β 2GP1: Beta2 glycoprotein 1; BMI: body mass index; LAC: lupus anticoagulant; NP: neuropsychiatric; SD: standard deviation; SDI: systemic lupus international collaborating clinics (SLICC)/American College of Rheumatology damage index; SLE: systemic lupus erythematosus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000.

[†] Only 278 patients were assessed for B2GP IgG and IgM

Relationship between groups of autoantibodies and SLE-associated MRI-brain lesions

The interaction between autoantibodies and NP-SLE status on MRI abnormalities was statistically significant in some of the cases (several not even statistically significant), but not clinically relevant (i.e. difference in the ORs between the 2 groups was not substantial); therefore, we decided to run the analysis in the whole population. Relationship between groups of autoantibodies and SLE-associated MRI-brain lesions are shown in **Table 3**. No relationship was found between the total number of SLE-related autoantibodies and MRI-brain abnormalities. Univariable analysis showed an association between an increasing

Table 2. Brain-MRI findings of the 325 SLE included patients

	n (%)
Normal MRI	83 (25.5)
Restricted diffusion	3 (0.9)
Gyral T2 hyperintensities	3 (0.9)
Gyral T1 hyperintensities	1 (0.3)
White matter lesions	
Periventricular WMHs	166 (51.1)
Deep WMHs	204 (62.8)
Subcortical	196 (60.3)
Fazekas score	
0	96 (29.5)
1	168 (51.7)
2	49 (15.1)
3	12 (3.7)
Basal Ganglia	6 (1.8)
Thalamus	5 (1.5)
Brainstem	25 (7.7)
Cerebellum	6 (1.8)
Lacunar infarcts	68 (20.9)
White matter supratentorial	38 (11.7)
Basal ganglia	24 (7.4)
Thalamus	10 (3.1)
Brainstem	7 (2.2)
Cerebellum	39 (12)
Large vessel infarcts	14 (4.3)
Sinus thrombosis	8 (2.5)
Focal white matter lesions	6 (1.8)
Parenchymal enhancement*	11 (3.4)
Leptomeningeal enhancement*	2 (0.6)
Inflammatory-like lesions*	19 (6)
Micro-haemorrhages	17 (5.2)
Large Haemorrhages	7 (2.2)
Gliososis	34 (10.5)
Cerebrocalcinosi	1 (0.3)
Cerebral atrophy (Pasquier scale)	
0	160 (49.2)
1	121 (37.2)
2	34 (10.5)
3	10 (3.1)

MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; WMHs: white matter hyperintensities.

* In 10 patients gadolinium was not used due to previous contrast allergy or because patient denied the use of contrast.

number of positive aPL antibodies and the presence of lacunar infarcts, CMBs, gliosis and atrophy. After adjustment for potential confounders, a significant relationship was only found for the increasing number of positive aPL antibodies and the presence of lacunar infarcts (OR 1.37 (1.02-1.99); $P < 0.05$) and gliosis (OR 2.15 (1.37-3.37); $P < 0.05$). None of the groups of autoantibodies was related to WMHs or inflammatory-like lesions. The clinical NP-status did not confound any of the relationships of interest and was therefore not kept in the models (data not shown). In the sensitivity analysis, after the inclusion of anti- β 2GP1 in the aPL antibodies group, only the relationship between the total number of aPL and gliosis (OR 1.56 (1.10-2.20); $P < 0.001$) remained significant after multivariable analysis (**Supplementary Table 3**).

Relationship between individual autoantibodies, CVD risk factors, SLE-specific factors and SLE-associated MRI-brain abnormalities

Associations between brain-MRI abnormalities, individual autoantibodies, CVD risk factors and other SLE-related factors are shown in **Table 4**. Patients with hypertension had a higher odds of a high Fazekas score (OR 5.61 (2.52-12.48); $P < 0.001$). SLE patients with hypertension (OR 2.52 (1.10-5.74); $P < 0.05$), positivity for LAC (OR 3.38 (1.32-8.68); $P < 0.05$) and higher SDI (OR 1.43 (1.07-1.90); $P < 0.05$) presented a higher chance for lacunar infarcts in WM. Hypertension (OR 8.34 (2.19-31.70); $P < 0.05$), male gender and higher SDI (OR 1.72 (1.18-2.51); $P < 0.05$) were associated with lacunar infarcts in basal ganglia. Furthermore, SDI was also associated with the presence of infarcts in the cerebellum (OR 1.79 (1.33-2.41); $P < 0.05$). aCL IgG was associated with gliosis (OR 2.71 (1.05-7.02); $P < 0.05$) and LAC with cerebral atrophy (OR 2.49 (1.01-6.15); $P < 0.05$). Again, the clinical NP-status did not confound any of the relationships of interest and was therefore not kept in the models. All these significant relationships were confirmed in the sensitivity analysis. In the main analysis, anti-RNP antibodies were related to the presence of inflammatory-like lesions; however, this relationship was not confirmed in the sensitivity analysis. Other CVD risk factors were not associated with brain abnormalities (**Supplementary Table 4**).

Table 3. Relationship between groups of auto-antibodies and MRI-brain lesions in 325 SLE patients

	WMH		Ischemic changes [†]		Gliosis		Inflammatory-like changes		Atrophy [‡]	
	Fazekas [§]	OR (95% CI)	Lacunar infarcts	OR (95% CI)	Micro-hemorrhages	OR (95% CI)	Gliosis	OR (95% CI)	Inflammatory-like changes	OR (95% CI)
Antiphospholipid antibodies (0-3)	Univariable	1.11 (0.79-1.54)	1.45 (1.07-1.97) ^a	OR (95% CI)	1.62 (1.01-2.63)^a	OR (95% CI)	2.24 (1.52-3.29)^b	OR (95% CI)	1.39 (0.84-2.30)	1.51 (1.07-2.16)^a
	Multivariable*	1.18 (0.79-1.76)	1.37 (1.02-1.99) ^a	OR (95% CI)	1.46 (0.81-2.65)	OR (95% CI)	2.15 (1.37-3.37)^b	OR (95% CI)	1.46 (0.82-2.61)	1.395 (0.92-2.13)
SLE related antibodies (0-5)	Univariable	0.81 (0.62-1.07)	0.82 (0.63-1.08)	OR (95% CI)	0.77 (0.48-1.23)	OR (95% CI)	0.76 (0.52-1.11)	OR (95% CI)	1.01 (0.65-1.54)	0.766 (0.55-1.07)
	Multivariable*	0.84 (0.61-1.17)	0.91 (0.66-1.25)	OR (95% CI)	0.74 (0.42-1.30)	OR (95% CI)	0.88 (0.58-1.34)	OR (95% CI)	1.07 (0.67-1.72)	0.795 (0.55-1.16)

MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; WMH: white matter hyperintensities.

Antiphospholipid antibodies included lupus anticoagulant, anticardiolipin IgM and IgG; SLE related antibodies included anti-dsDNA, anti-SSA/Ro52, anti-SSB/La, anti-Sm and anti-rNP.

*Multivariable analysis was adjusted for age, gender, hypertension, smoking (current or ever), BMI, dyslipidemia, diabetes mellitus, low C3, low C4, duration of SLE, SLEDAI-2K and SDI.

† Lacunar infarcts load includes: white matter, basal ganglia, thalamus, brainstem and cerebellum infarcts. No associations were found for large vessel infarcts, large hemorrhages and sinus thrombosis.

‡ Pasquier scale ≥ 2.

§ Reference Fazekas score ≤ 1.

a. P < 0.05; b. P < 0.001.

Table 4. Relationship between individual auto-antibodies and MRI-brain lesions in 325 SLE patients.

	WMH				Ischemic changes ^a				Inflammatory-like changes				Atrophy ^a	
	Fazekas ^b OR (95% CI)	White matter OR (95% CI)	Basal Ganglia OR (95% CI)	Thalamus OR (95% CI)	Cerebellum OR (95% CI)	Large vessel infarcts	Micro- hemorrhages	Gliosis	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
aCL IgG	0.89 (0.31-2.61)	0.84 (0.32-2.52)	0.70 (0.15-3.14)	8.75 (1.24-62.09)^a	1.34 (0.50-3.61)	2.20 (0.50-9.82)	1.11 (0.31-3.95)	2.71 (1.05-7.02)^a	1.16 (0.34-4.00)	1.05 (0.40-2.72)				
aCL IgM	0.54 (0.13-2.35)	0.38 (0.08-1.79)	1.02 (0.17-5.94)	5.46 (0.79-37.92)	0.94 (0.26-3.37)	5.31 (0.93-30.32)	0.61 (0.10-3.57)	2.01 (0.62-6.51)	1.72 (0.40-7.38)	0.91 (0.28-2.94)				
LAC	1.64 (0.64-4.22)	3.98 (1.32-8.68)^a	0.68 (0.18-2.51)	1.24 (0.19-8.12)	1.87 (0.75-4.69)	1.04 (0.23-4.70)	2.03 (0.59-6.97)	1.98 (0.75-5.24)	1.62 (0.51-5.12)	2.49 (1.01-6.15)^a				
Anti-dsDNA	0.77 (0.37-1.63)	0.62 (0.27-1.44)	1.29 (0.45-3.68)	0.42 (0.08-2.20)	1.31 (0.57-2.99)	0.34 (0.08-1.37)	0.95 (0.29-3.13)	1.08 (0.45-2.62)	1.09 (0.37-3.22)	0.50 (0.23-1.11)				
Anti-SSA/Ro52	1.09 (0.47-2.55)	0.91 (0.37-2.23)	2.50 (0.76-8.25)	0.12 (0.01-1.76)	1.14 (0.46-2.97)	0.35 (0.06-1.99)	1.59 (0.49-5.13)	0.41 (0.13-1.36)	0.985 (0.33-2.98)	0.97 (0.41-2.30)				
Anti-SSB/La	1.37 (0.43-4.37)	0.70 (0.16-3.07)	0.85 (0.17-4.09)	4.48 (0.36-55.37)	2.10 (0.59-7.47)	6.00 (0.85-42.26)	3.68 (0.79-29.30)	3.57 (0.80-15.91)	0.00	0.87 (0.25-3.09)				
Anti-RNP	0.53 (0.17-1.64)	0.73 (0.22-2.46)	1.42 (0.35-5.71)	0.49 (0.05-5.19)	0.43 (0.11-1.62)	0.21 (0.02-2.09)	0.95 (0.20-4.43)	0.11 (0.01-0.91)^a	3.37 (1.01-10.56)^a	1.52 (0.56-4.14)				
Anti-Sm	1.07 (0.25-4.51)	0.98 (0.23-4.14)	0.44 (0.04-4.57)	4.38 (0.29-65.31)	0.68 (0.13-3.61)	6.25 (0.82-47.80)	0.37 (0.04-3.62)	2.08 (0.46-9.38)	1.06 (0.24-4.70)	0.46 (0.09-2.28)				
C3 low	0.91 (0.34-2.39)	0.92 (0.35-2.47)	0.96 (0.26-3.64)	3.66 (0.55-24.51)	1.44 (0.54-3.86)	1.01 (0.21-4.92)	3.93 (0.93-13.62)	1.07 (0.39-2.94)	0.45 (0.13-1.58)	1.75 (0.69-4.39)				
C4 low	1.11 (0.43-2.86)	1.00 (0.35-2.84)	3.42 (0.90-13.06)	0.51 (0.07-3.70)	0.59 (0.20-1.75)	0.29 (0.04-2.15)	1.01 (0.27-3.80)	1.60 (0.57-4.55)	1.19 (0.34-4.23)	0.98 (0.37-2.61)				
Age	1.05 (1.01-1.08)^a	1.02 (0.98-1.05)	1.01 (0.97-1.06)	1.03 (0.97-1.01)	1.03 (1.00-1.07)	1.02 (0.97-1.08)	1.06 (1.01-1.11)^a	1.01 (0.98-1.05)	1.00 (0.95-1.04)	1.05 (1.01-1.08)^a				
Gender	0.59 (0.21-1.66)	1.57 (0.40-6.14)	0.24 (0.06-0.94)^a	2.25 (0.17-30.62)	0.30 (0.10-0.88)^a	0.27 (0.05-1.46)	1.08 (0.17-6.88)	0.65 (0.18-2.32)	2.67 (0.31-23.20)	0.63 (0.22-1.79)				
Duration SLE	1.03 (0.99-1.07)	1.05 (1.01-1.10)^a	1.03 (0.97-1.08)	0.93 (0.84-1.03)	1.02 (0.97-1.06)	0.91 (0.82-1.01)	1.04 (0.98-1.10)	1.00 (0.95-1.05)	1.01 (0.94-1.08)	1.04 (1.01-1.08)^a				
SLEDAI-2K	1.02 (0.93-1.11)	1.03 (0.94-1.12)	0.89 (0.77-1.03)	0.97 (0.81-1.17)	1.02 (0.94-1.11)	1.00 (0.87-1.15)	1.01 (0.90-1.14)	0.93 (0.84-1.03)	1.00 (0.91-1.11)	1.07 (0.99-1.16)				
SDI	0.91 (0.68-1.22)	1.43 (1.07-1.90)^a	1.72 (1.18-2.51)^a	1.41 (0.73-2.71)	1.79 (1.33-2.41)^a	2.07 (1.23-3.50)^a	1.23 (0.83-1.82)	1.60 (1.17-2.18)^a	1.46 (0.97-2.18)	1.23 (0.97-1.62)				
Hypertension	5.61 (2.52-12.48)^a	2.52 (1.10-5.74)^a	8.34 (2.19-31.70)^a	7.62 (1.06-57.77)^a	1.98 (0.89-4.44)	0.98 (0.25-3.88)	1.47 (0.47-4.57)	1.77 (0.72-4.36)	0.79 (0.25-2.55)	1.92 (0.91-4.07)				
Smoking Current	2.45 (0.89-6.74)	1.24 (0.45-3.39)	1.47 (0.39-5.52)	1.45 (0.17-12.49)	0.59 (0.20-1.72)	0.46 (0.10-2.13)	5.12 (0.90-29.13)	0.84 (0.26-2.75)	0.41 (0.09-1.95)	1.06 (0.39-2.88)				
Ever	0.52 (0.21-1.35)	2.22 (0.85-5.83)	2.21 (0.60-8.13)	0.69 (0.07-6.96)	1.64 (0.64-4.21)	4.78 (0.88-26.04)	0.25 (0.05-1.28)	1.06 (0.37-3.07)	1.37 (0.43-4.32)	1.04 (0.42-2.57)				
BMI	0.99 (0.93-1.07)	0.99 (0.92-1.08)	1.02 (0.93-1.12)	1.07 (0.91-1.26)	1.01 (0.94-1.09)	1.04 (0.90-1.19)	0.98 (0.86-1.11)	1.01 (0.93-1.10)	0.89 (0.79-1.01)	1.05 (0.98-1.13)				
Dyslipidemia	1.44 (0.71-2.93)	0.99 (0.45-2.20)	0.70 (0.25-1.92)	2.28 (0.45-11.69)	0.93 (0.42-2.08)	0.60 (0.16-2.22)	0.39 (0.12-1.26)	0.59 (0.25-1.42)	0.66 (0.21-2.10)	1.42 (0.67-3.01)				
Diabetes	1.52 (0.37-6.29)	0.15 (0.01-1.62)	0.93 (0.13-6.68)	0.58 (0.03-10.67)	0.54 (0.10-2.90)	0.44 (0.02-9.30)	0.38 (0.03-5.87)	1.02 (0.17-6.20)	1.56 (0.15-16.67)	0.84 (0.21-3.46)				

aCL: anticardiolipin; BMI: body mass index; C3: complement component 3; C4: complement component 4; LAC: lupus anticoagulant; MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; SLEDAI-2K: systemic lupus erythematosus disease activity index 2000; SDI: SLICC (systemic lupus international clinics) damage index; WMH: white matter hyperintensities.

† No association was found for lacunar infarcts in the brainstem, large hemorrhages and sinus thrombosis.

* Reference Fazekas score ≤ 1 .

a. $P < 0.05$; b. $P < 0.001$.

DISCUSSION

In the present study, we have demonstrated the association of aPL, especially LAC, cumulative SLE-organ damage and several CVD risk factors and the presence of ischemic changes in the brain of SLE patients. On the other hand, SLE-related autoantibodies in serum, both total number and individual autoantibodies, were not associated with inflammatory-like lesions or other brain-MRI abnormalities.

Ischemic changes in the brain of SLE patients seem to be driven by aPL. Among all the serum autoantibodies analyzed, LAC, but not aCL or anti- β 2GP1 were associated with lacunar infarcts in the WM and also with cerebral atrophy. Previous reports have also found that LAC is a major risk factor for arterial thrombotic disease, especially for ischemic stroke in young women.(35,36) Furthermore, a higher prevalence of MRI abnormalities, mainly lacunar and large territorial infarctions, has been found in SLE patients with antiphospholipid syndrome;(21,37) LAC has been suggested to play the most important role in this association. (20) The relation between LAC and cerebral atrophy is more inconsistent. This relationship has been found using the Pasquier scale in a small study in SLE patients and another study including only NP-SLE patients without correction for other variables.(22,38) Other studies failed to demonstrate any significant association between LAC and cerebral atrophy, even when quantitative MRI-methods were used.(37,39) aCL IgG was related to gliosis. We hypothesize that gliosis seen in the brain of SLE patients is driven by aCL IgG and may be part of an underlying ischemic process or due to an autoimmune-mediated glial activation.

Inflammatory-like lesions in the brain of SLE patients were not found to be related to the total number of SLE-related autoantibodies. There may be different possible explanations for these negative findings. We report a low prevalence of inflammatory-like lesions (5.8%). In the presence of a low frequency of brain-MRI inflammatory-like lesions, it is difficult to capture factors associated with it due to a lack of power. Notwithstanding, it is difficult to interpret this frequency, as in the literature there are no other studies reporting the prevalence of inflammatory-like lesions. The MRI may have shown no abnormalities despite overt NP-SLE manifestations as it has been demonstrated with other quantitative MRI-techniques.(24,40) Moreover, the inflammatory-like lesions included are still a group of heterogeneous MRI changes which may reflect different pathophysiological changes. Another reason may be the autoantibodies selected for our analysis. In the future, other serum autoantibodies (i.e. anti-ribosomal P or anti-NMDA-receptor) and autoantibodies acquired from cerebrospinal fluid (CSF) may yield stronger associations when associated with quantitative MRI-techniques.

Other mechanisms, such as SLE-related and CVD risk factors, showed a correlation with brain-MRI abnormalities in SLE. Cumulative SLE organ-damage measured with SDI was

found to be associated with lacunar infarcts in WM, basal ganglia and cerebellum and with cerebral atrophy. Contrary to previous reports, SDI was not related to WMHs.(41) The presence of brain-MRI abnormalities in general has been previously related to higher disease severity scores and the need for more aggressive therapy.(42) Our data suggest that both infarcts and cerebral atrophy are related to chronic SLE-related damage in other organs. Therefore, patients with these brain-MRI abnormalities may have a more severe disease but also more damage due to systemic accelerated atherosclerosis affecting the whole arterial tree, which points to the importance of thrombotic/ischemic nature in leading to SLE-related damage.(43) In general population, the presence of atherosclerosis measured by carotid intima media thickness has been related to an increased risk for brain atrophy.(44) This accelerated atherogenesis in combination with other factors such as LAC and duration of disease may lead to brain infarcts and to increased brain atrophy in SLE. Early diagnosis, meticulous monitoring of SLE activity and effective use of immunosuppressive therapy may help avoiding SLE-related organ damage.

Among the CVD risk factors, hypertension was correlated with higher Fazekas score and lacunar infarcts. A relationship between long-standing hypertension and the presence of WMHs has been also described in a prospective study in a healthy population. (45) Furthermore, the strongest risk factor for ischemic stroke in general population is hypertension.(46) Wiseman *et al.* showed recently an association between Fazekas score and age and hypertension in SLE patients after unadjusted univariable association.(47) Our results confirm this association after correcting for multiple confounding factors and even when the influence of the clinical status (non-NP-SLE vs. NP-SLE) was taken into account. Contrary to a previous longitudinal SLE study(19), correlations between WMHs and aPL or SDI were not found. The different method used to assess WMHs in this previous study, semiautomatic volumetric measurements instead of Fazekas score, may explain these differences. Although hypertension and not antibodies such as aCL seem to play the most important role in the genesis of WMHs, we believe that there may be other unknown SLE and non-SLE-related contributing factors leading to WMHs. Compromised BBB integrity has been recently suggested as a contributor in the pathogenesis of WMHs in healthy population.(48) Future studies on SLE analyzing if adequate treatment of hypertension may prevent WMHs and atherosclerosis and the contribution of BBB permeability in the pathogenesis of WMHs are warranted.

Some limitations of this study should be taken into account. Due to the characteristics of our cohort and referral nuances, we were not able to measure ultrasound carotid atherosclerosis markers or to calculate the cumulative dose of corticosteroids and its effect in the brain could not be investigated. Lumbar puncture is not routinely performed in patients included in our cohort; therefore, we lack the results of CSF autoantibodies. Another limitation lies on

the fact that MRIs were scored only by one reader. The cross-sectional study design does not allow an interpretation of temporal or causal relationships. Another limitation may be the use of the visual Fazekas score and Pasquier scale for assessing WMHs and brain atrophy, respectively. Although these are widely used and accepted methods, the use of automated or semi-automated computer programs for quantifying lesion load and volume of WMHs and to assess measures of whole-brain atrophy may be more accurate.

Our study has important strengths. So far, most of the studies have focused in small groups of NP-SLE patients or in the difference between NP-SLE and SLE patients. In contrary, we decided to include all SLE patients in the study and focus in the nature of the MRI abnormalities. We have looked into the potential modification role of the NP clinical status in the association between the investigated antibodies and the brain-MRI alterations, which was not confirmed. Furthermore, since MRI abnormalities were probably used to establish a NP-SLE diagnosis, these studies would not avoid a certain level of selection bias and circular reasoning. It is also important to consider that a proportion of patients have abnormal MRI patterns without overt clinical symptoms or a normal MRI while presenting severe NP-SLE. (42) Thus, we are convinced that including all SLE patients in the study better captures the possible underlying pathophysiological mechanisms of these MRI abnormalities. Another strength of our study is that we assessed all patients with the same high field strength (3T) using a standardized MRI-protocol. To date, most studies included MRI-scans performed using different field strengths or using lower field strength (0.5-1.5T).

In summary, there is no indication that the total number or the individual SLE-related autoantibodies are associated with inflammatory-like lesions on the brain-MRI but the total number of aPL, especially the positivity for LAC, are associated with ischemic brain changes, mainly with lacunar infarcts and cerebral atrophy. Furthermore, cumulative SLE-organ damage and modifiable CVD risk factors, such as hypertension, contribute to these ischemic changes pointing out the importance of systemic accelerated atherosclerosis in SLE. We suggest that future studies should focus on CSF and other serum autoantibodies and their relationship with MRI abnormalities. Moreover, the inclusion of quantitative MRI-techniques at this point may help to better understand the underlying pathophysiological processes at a microstructural level.

REFERENCES

1. Tsokos GC. Systemic lupus erythematosus. *N Engl J Med* 2011;365:2110-21.
2. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. *Drugs* 2016;76:459-83.
3. Crow MK. Type I interferon in the pathogenesis of lupus. *J Immunol* 2014;192:5459-68.
4. Bialas AR, Presumey J, Das A, van der Poel CE, Lapchak PH, Mesin L, et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. *Nature* 2017;546:539-43.
5. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* 2016;352:712-6.
6. Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. *Ann Rheum Dis* 2016;75:2014-21.
7. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. *Arthritis Rheum* 2007;56:3112-24.
8. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. *Blood* 2006;107:3229-34.
9. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat Immunol* 2007;8:487-96.
10. Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT. Losing your nerves? Maybe it's the antibodies. *Nat Rev Immunol* 2009;9:449-56.
11. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. *Nat Med* 2001;7:1189-93.
12. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. *Proc Natl Acad Sci U.S.A.* 2006;103:19854-9.
13. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. *Ann Rheum Dis* 2011;70:1726-32.
14. Magro-Checa C, Schaarenburg RA, Beart HJ, Huizinga TW, Steup-Beekman GM, Trouw LA. Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. *Lupus* 2016;25:878-88.
15. Cavazzana I, Manuela N, Irene C, Barbara A, Sara S, Orietta BM, et al. Complement activation in antiphospholipid syndrome: a clue for an inflammatory process? *J Autoimmun* 2007;28:160-4.
16. Cohen D, Rijnink EC, Nabuurs RJ, Steup-Beekman GM, Versluis MJ, Emmer BJ, et al. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. *Rheumatology (Oxford)* 2017;56:77-86.
17. Piga M, Peltz MT, Montaldo C, Perra D, Sanna G, Cauli A, et al. Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement. *Autoimmun Rev* 2015;14:510-6.
18. Sibbitt WL, Jr., Brooks WM, Kornfeld M, Hart BL, Bankhurst AD, Roldan CA. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. *Semin Arthritis Rheum* 2010;40:32-52.
19. Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. *Ann Neurol* 2008;64:635-43.
20. Csepany T, Bereczki D, Kollar J, Sikula J, Kiss E, Csiba L. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. *J Neurol* 2003;250:1348-54.
21. Kaichi Y, Kakeda S, Moriya J, Ohnari N, Saito K, Tanaka Y, et al. Brain MR findings in patients with systemic lupus erythematosus with and without antiphospholipid antibody syndrome. *AJNR Am J Neuroradiol* 2014;35:100-5.
22. Sarbu N, Alobeidi F, Toledano P, Espinosa G, Giles I, Rahman A, et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort.

Autoimmun Rev 2015;14:153-9.

23. Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. *J Rheumatol* 2008;35:2348-54.
24. Luyendijk J, Steens SC, Ouwendijk WJ, Steup-Beekman GM, Bollen EL, van der Grond J, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. *Arthritis Rheum* 2011;63:722-32.
25. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.
26. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
27. Zirkzee EJ, Steup-Beekman GM, van der Mast RC, Bollen EL, van der Wee NJ, Baptist E, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. *J Rheumatol* 2012;39:2118-26.
28. Magro-Checa C, Zirkzee EJ, Beart-van de Voorde LJJ, Middelkoop HA, van der Wee NJ, Huisman MV, et al. Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. *Rheumatology (Oxford)* 2017;56:1676-83.
29. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *AJR Am J Roentgenol* 1987;149:351-6.
30. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013;12:822-38.
31. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. *Eur Neurol* 1996;36:268-72.
32. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002;29:288-91.
33. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. *J Rheumatol* 2000;27:373-6.
34. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143-421.
35. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. *Lancet Neurol* 2009;8:998-1005.
36. Siegerink B, Maino A, Algra A, Rosendaal FR. Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women. *J Thromb Haemost* 2015;13:1568-75.
37. Valdes-Ferrer SI, Vega F, Cantú-Brito C, Ceballos-Ceballos J, Estañol B, García-Ramos G, et al. Cerebral changes in SLE with or without antiphospholipid syndrome. a case-control MRI study. *J Neuroimaging* 2008;18:62-5.
38. Hachulla E, Michon-Pasturel U, Leys D, Pruvo JP, Queyrel V, Masy E, et al. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies. *Lupus* 1998;7:124-31.
39. Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. *Arthritis Rheum* 2005;52:2783-9.
40. Magro-Checa C, Ercan E, Wolterbeek R, Emmer B, van der Wee NJ, Middelkoop HA, et al. Changes in White Matter Microstructure Suggest an Inflammatory Origin of Neuropsychiatric Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2016;68:1945-54.
41. Ainiäla H, Dastidar P, Loukkola J, Lehtimäki T, Korpela M, Peltola J, et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. *Scand J Rheumatol* 2005;34:376-82.
42. Cauli A, Montaldo C, Peltz MT, Nurchis P, Sanna G, Garau P, et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. *Clin Rheumatol* 1994;13:615-8.
43. Mak A, Isenberg DA, Lau CS. Global trends, potential mechanisms and early detection of organ damage in SLE. *Nat Rev Rheumatol* 2013;9:301-10.
44. Sabayan B, van Buchem MA, Sigurdsson S, Zhang Q, Meirelles O, Harris TB, et al. Cardiac and Carotid Markers Link With Accelerated Brain Atrophy: The AGES-Reykjavik Study (Age, Gene/Environment Susceptibility-Reykjavik). *Arterioscler*


Thromb Vasc Biol 2016;36:2246-51.

45. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. *Brain* 2002;125:765-72.
46. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. *Lancet* 1995;346:1647-53.
47. Wiseman SJ, Bastin ME, Jardine CL, Barclay G, Hamilton IF, Sandeman E, et al. Cerebral Small Vessel Disease Burden Is Increased in Systemic Lupus Erythematosus. *Stroke* 2016;47:2722-8.
48. Li Y, Li M, Zhang X, Shi Q, Yang S, Fan H, et al. Higher blood-brain barrier permeability is associated with higher white matter hyperintensities burden. *J Neurol* 2017.


SUPPLEMENTARY MATERIAL

Supplementary Table 1. Scanning parameters

Sequence	T2-Weighted	3D T1-Weighted	3D FLAIR	3D T2-Weighted	3D T1-weighted with Gadolinium	SWI
Orientation	AX	AX	SAG	SAG	AX	AX
Scan Technique	Spin Echo	Gradient Echo	Inversion Recovery	Spin Echo	Gradient Echo	Gradient Echo
Scan Mode	Multi Slice	3D	3D	3D	3D	3D
TR	4158 ms	9.8 ms	4800 ms	2500 ms	9.8 ms	45 ms
TE	80 ms	4.6 ms	311 ms	317 ms	4.6 ms	31 ms
Inversion time (TI)			1650 ms			
Flip Angle	90	8		90	8	13
FOV	224 mm x 180 mm	224 mm x 177 mm	220 mm x 220 mm	250 mm x 250 mm	224 mm x 177 mm	250 mm x 181 mm
Acq. Matrix	448 x 319	192 x 152	200 x 197	208 x 208	192 x 152	320 x 226
Resolution (acquired)	0.50 mm x 0.56 mm	1.17 mm x 1.17 mm	1.10 mm x 1.11 mm	1.20 mm x 1.20 mm	1.17 mm x 1.17 mm	0.78 mm x 0.78 mm
Resolution (reconstructed)	0.22 mm x 0.22 mm	0.88 mm x 0.88 mm	0.98 mm x 0.98 mm	1.12 mm x 1.12 mm	0.88 mm x 0.88 mm	0.78 mm x 0.78 mm
Slice Thickness	3.6 mm	1.2 mm	0.56 mm	0.6 mm	1.2 mm	0.8 mm
Number of Slices	40	120	310	300	120	180
Fold-over Direction	RL	RL	AP	AP	RL	RL
Band width	200 Hz	140.6 Hz	1041.7 Hz	387.7 Hz	140.6 Hz	111.1 Hz
SENSE Factor	RL = 2		AP = 2.6, RL = 2	AP = 2, RL = 2		RL = 2
TSE Factor	16		182	100		
TFE Factor		154			154	
Fat Suppression			SPIR	SPIR		
NEX	2	1	2	1	1	1
Acquisition Time (min:sec)	02:54.6	04:37.6	04:04.8	02:32.5	04:37.6	03:17.0




Supplementary Figure 1. White matter hyperintensities. Fazekas 2, scattered hyperintensities in the periventricular and deep white matter beginning to confluence on axial FLAIR (A) and axial T2-weighted (B). Fazekas 3, confluent hyperintensities on FLAIR (C) and T2-weighted (D) images in the periventricular, deep white matter and subcortical white matter (no restricted diffusion). Acute infarct in right parieto-occipital lobe seen on diffusion weighted imaging (DWI) $b=1000$ (E), apparent diffusion coefficient (ADC) (F), axial FLAIR (G) and T1-weighted post-contrast (H) images. Restricted diffusion in the right parieto-occipital lobe i.e. high signal on DWI and corresponding low signal on ADC. Subtle high signal on FLAIR in the right parieto-occipital lobe and no change on the T1-weighted image.



Supplementary Figure 2. Subacute hemorrhages seen in bilateral lentiform nuclei and right parietal lobe, as bright signal on T1-weighted (A) and T2-weighted (B) images surrounded by a dark rim of hemosiderin on susceptibility weighted imaging (SWI) (C).

5



Supplementary Figure 3. Inflammatory lesion seen on axial FLAIR (A), axial T2-weighted (B), axial T1-weighted before contrast (C) and T1-weighted post-contrast (D). A new T2 and FLAIR hyperintense lesion in the left frontal periventricular white matter with enhancement (red arrow). Old infarcts in the cerebellar hemispheres (E), right parietal lobe and in the left basal ganglia (F) seen on axial T2-weighted images.

Supplementary Table 2. Brain-MRI findings in 325 SLE patients after attribution of NP events

	Non-NP-SLE (n = 204) n (%)	Ischemic NP-SLE (n = 43) n (%)	Inflammatory NP-SLE (n = 78) n (%)
Normal MRI	65 (32.9)	2 (4.7)	16 (20.5)
Restricted diffusion	0 (0)	0 (0)	3 (3.8)
Gyral T2 hyperintensities	2 (1)	0 (0)	1 (1.3)
Gyral T1 hyperintensities	0 (0)	1 (2.3)	0 (0)
White matter lesions			
Periventricular WMHs	95 (46.6)	30 (69.8)	41 (52.6)
Deep WMHs	115 (56.4)	32 (74.4)	57 (73.1)
Subcortical	113 (55.4)	31 (72.1)	52 (66.7)
Fazekas score			
0	74 (36.3)	6 (14)	16 (20.5)
1	99 (48.5)	22 (51.2)	47 (60.3)
2	24 (11.8)	12 (27.9)	13 (16.7)
3	7 (3.4)	3 (7)	2 (2.6)
Basal Ganglia	4 (2)	1 (2.3)	1 (1.3)
Thalamus	3 (1.5)	1 (2.3)	1 (1.3)
Brainstem	18 (8.8)	5 (11.6)	2 (2.6)
Cerebellum	2 (1%)	2 (4.7)	2 (2.6)
Lacunar infarcts	29 (14.2)	22 (51.2)	17 (21.8)
White matter supratentorial	16 (7.8)	12 (27.9)	10 (12.8)
Basal ganglia	11 (5.4)	7 (16.3)	6 (7.7)
Thalamus	3 (1.5)	5 (11.6)	2 (2.6)
Brainstem	3 (1.5)	3 (7)	1 (1.3)
Cerebellum	17 (8.3)	12 (27.9)	10 (12.8)
Large vessel infarcts	4 (2)	7 (16.3)	3 (3.8)
Sinus thrombosis	0 (0)	6 (14)	2 (2.6)
Focal white matter lesions	1 (0.5)	1 (2.3)	4 (5.1)
Parenchymal enhancement*	5 (2.5)	4 (9.3)	2 (2.6)
Leptomeningeal enhancement*	1 (0.5)	1 (2.3)	0 (0)
Inflammatory-like lesions*	6 (2.9)	7 (16.3)	6 (7.7)
Micro-haemorrhages	9 (4.4)	3 (7)	5 (6.41)
Large Haemorrhages	4 (2)	3 (7)	0 (0)
Gliosis	12 (5.9)	14 (32.6)	8 (10.3)
Cerebrocalcinosis	0 (0)	1 (2.3)	0 (0)
Cerebral atrophy (Pasquier scale)			
0	103 (50.5)	19 (44.2)	38 (48.7)
1	81 (39.7)	13 (30.2)	27 (34.6)
2	16 (7.8)	6 (14)	12 (15.4)
3	4 (2)	5 (11.6)	1 (1.3)

MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; WMHs: white matter hyperintensities.

* In 10 patients gadolinium was not used due to previous contrast allergy or because patient denied the use of contrast.

Supplementary Table 3. Sensitivity analysis including anti-β2 glycoprotein 1 IgG and IgM in the model. Relationship between groups of auto-antibodies and MRI-brain lesions in 278 SLE patients

	WMH	Ischemic changes [†]		Gliosis	Inflammatory-like changes		Atrophy [‡]
		Fazekas [§] OR (95% CI)	Lacunar infarcts OR (95% CI)		OR (95% CI)	OR (95% CI)	
Antiphospholipid antibodies (0-5)	Univariable	1.03 (0.79-1.33)	1.18 (0.93-1.49)	1.60 (1.20-2.14)^b	OR (95% CI)	1.11 (0.75-1.63)	OR (95% CI)
	Multivariable*	1.04 (0.76-1.43)	1.07 (0.81-1.43)	1.56 (1.10-2.20)^b	OR (95% CI)	1.15 (0.73-1.80)	1.36 (0.99-1.87)
SLE related antibodies (0-5)	Univariable	0.87 (0.65-1.17)	0.87 (0.65-1.16)	0.85 (0.56-1.29)	OR (95% CI)	1.10 (0.72-1.70)	0.77 (0.53-1.11)
	Multivariable*	0.91 (0.64-1.29)	0.89 (0.64-1.24)	0.93 (0.58-1.48)	OR (95% CI)	1.15 (0.72-1.85)	0.81 (0.53-1.22)

MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; WMH: white matter hyperintensities.

Antiphospholipid antibodies included lupus anticoagulant, anticardiolipin IgM, anticardiolipin IgG, anti-β2 glycoprotein 1 IgG and IgM; SLE related antibodies included anti-dsDNA, anti-SSA/Ro52, anti-SSB/La, anti-Sm and anti-RNP.

*Multivariable analysis was adjusted for age, gender, hypertension, smoking (current or ever), BMI, dyslipidemia, diabetes mellitus, low C3, low C4, duration of SLE, SLEDAI-2K and SDI.

† Lacunar infarcts load includes: white matter, basal ganglia, thalamus, brainstem and cerebellum infarcts. No associations were found for large vessel infarcts, large hemorrhages, micro-hemorrhages and sinus thrombosis.

‡ Pasquier scale ≥ 2.

§ Reference Fazekas score ≤ 1.

a. P < 0.05; b. P < 0.001.

Supplementary Table 4. Sensitivity analysis including anti-β2 glycoprotein 1 IgG and IgM in the model. Relationship between individual auto-antibodies and MRI-brain lesions in 278 SLE patients.

	WMH		Ischemic changes ^a				Large vessel infarcts				Micro-hemorrhages				Gliosis		Inflammatory-like changes		Atrophy ^b	
	Fazekas ^c		Lacunar infarcts		Basal Ganglia		Cerebellum		Basal Ganglia		Cerebellum		Basal Ganglia		Cerebellum		Basal Ganglia		Cerebellum	
	OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)		OR (95% CI)	
aCL IgG	0.84 (0.24-3.01)		2.21 (0.57-8.54)		0.96 (0.13-7.12)		1.24 (0.33-4.71)		4.55 (0.46-44.81)		1.34 (0.19-9.71)		4.90 (1.30-18.55)^a		1.97 (0.43-9.10)		0.82 (0.23-2.98)			
aCL IgM	0.54 (0.11-2.75)		0.16 (0.01-1.99)		1.12 (0.12-10.10)		1.43 (0.29-7.20)		2.35 (0.10-54.93)		0.12 (0.01-3.47)		5.07 (0.95-27.14)		1.25 (0.11-13.68)		0.32 (0.06-1.76)			
LAC	1.61 (0.61-4.25)		3.88 (1.33-11.35)^a		0.79 (0.19-3.38)		1.62 (0.56-4.73)		2.19 (0.32-15.01)		1.72 (0.35-8.50)		2.40 (0.74-7.81)		1.43 (0.38-5.29)		3.05 (1.01-9.21)^a			
β2-GP1 IgG	1.12 (0.29-4.40)		0.24 (0.046-1.26)		0.34 (0.03-3.43)		1.51 (0.37-6.15)		0.06 (0.01-1.31)		0.41 (0.04-4.37)		0.42 (0.09-1.83)		0.00		2.92 (0.73-11.74)			
β2-GP1 IgM	1.01 (0.14-7.06)		0.00		0.65 (0.04-11.43)		0.45 (0.05-3.81)		0.00		7.78 (0.34-177.26)		0.07 (0.01-1.15)		16.29 (0.43-615.05)		0.60 (0.07-5.39)			
Anti-dsDNA	0.78 (0.37-1.64)		0.48 (0.18-1.29)		1.14 (0.36-3.68)		1.17 (0.47-2.89)		0.74 (0.14-3.93)		0.51 (0.11-2.36)		1.85 (0.62-5.53)		1.475 (0.44-5.01)		0.57 (0.23-1.42)			
Anti-SSA/Ro52	1.10 (0.47-2.55)		0.97 (0.35-2.70)		3.00 (0.83-10.81)		1.18 (0.42-3.30)		0.62 (0.08-4.61)		1.14 (0.29-4.41)		0.53 (0.14-2.02)		1.56 (0.44-5.56)		1.23 (0.46-3.28)			
Anti-SSB/La	1.37 (0.43-4.37)		1.07 (0.23-4.99)		0.78 (0.14-4.01)		2.07 (0.54-7.93)		4.06 (0.38-43.50)		0.00		2.32 (0.38-14.28)		0.00		0.69 (0.15-3.11)			
Anti-RNP	0.53 (0.17-1.68)		0.63 (0.17-2.37)		1.27 (0.30-5.38)		0.42 (0.11-1.64)		0.24 (0.02-3.24)		1.32 (0.24-7.15)		0.13 (0.01-1.29)		3.01 (0.82-11.03)		1.93 (0.62-6.01)			
Anti-Sm	1.07 (0.25-4.51)		0.67 (0.12-3.78)		0.39 (0.04-4.19)		0.74 (0.13-4.19)		5.80 (0.37-90.33)		0.50 (0.03-7.42)		0.91 (0.08-9.84)		1.01 (0.17-6.03)		0.29 (0.03-2.57)			
Low serum C3	0.89 (0.34-2.39)		1.92 (0.62-5.94)		1.44 (0.34-6.20)		1.72 (0.60-4.95)		3.56 (0.41-30.69)		4.16 (0.88-19.71)		1.59 (0.48-5.29)		0.32 (0.07-1.476)		1.10 (0.37-3.25)			
Low serum C4	1.11 (0.43-2.86)		0.96 (0.30-3.10)		3.14 (0.77-12.81)		0.56 (0.18-1.75)		0.18 (0.01-2.52)		1.39 (0.32-6.10)		2.18 (0.64-7.40)		1.57 (0.37-6.74)		1.12 (0.37-3.40)			
Age	1.05 (1.01-1.08)^a		1.02 (0.97-1.06)		1.00 (0.95-1.06)		1.03 (0.99-1.07)		1.04 (0.96-1.12)		1.08 (1.01-1.14)^a		1.01 (0.96-1.06)		0.99 (0.95-1.05)		1.06 (1.02-1.10)^a			
Gender	0.60 (0.21-1.70)		0.93 (0.22-3.91)		0.20 (0.04-0.99)^a		0.37 (0.12-1.18)		0.15 (0.02-0.99)^a		1.07 (0.11-10.87)		0.64 (0.15-2.80)		2.30 (0.23-23.01)		0.63 (0.20-1.97)			
Duration SLE	1.03 (0.39-1.07)		1.04 (0.99-1.09)		1.02 (0.96-1.09)		1.01 (0.96-1.06)		0.94 (0.85-1.04)		1.04 (0.97-1.12)		1.01 (0.95-1.07)		1.01 (0.94-1.08)		1.06 (1.01-1.11)^a			
SLEDAI-2K	1.02 (0.93-1.11)		1.00 (0.91-1.11)		0.89 (0.76-1.03)		1.01 (0.93-1.11)		1.02 (0.86-1.20)		1.00 (0.86-1.16)		0.88 (0.78-1.01)		0.98 (0.88-1.10)		1.10 (0.99-1.21)			
SDI	0.91 (0.67-1.22)		1.60 (1.14-2.26)^a		1.87 (1.23-2.84)^a		1.85 (1.35-2.58)^a		1.49 (0.83-2.70)		1.20 (0.74-1.95)		1.39 (0.95-2.03)		1.52 (0.99-2.35)		1.45 (1.06-1.99)^a			
Hypertension	5.61 (2.52-12.49)^a		3.27 (1.21-8.82)^a		6.42 (1.62-25.52)^a		1.44 (0.59-3.50)		2.10 (0.38-11.61)		1.93 (0.44-8.46)		3.45 (1.08-11.03)		0.73 (0.20-2.64)		1.24 (0.52-2.94)			
Smoking Current	2.45 (0.89-6.76)		1.79 (0.58-5.82)		1.27 (0.31-5.22)		0.58 (0.19-1.90)		0.54 (0.09-3.29)		6.44 (0.90-46.17)		0.63 (0.16-2.37)		0.33 (0.05-2.12)		1.71 (0.57-5.12)			
Ever	0.52 (0.20-1.34)		2.82 (0.94-8.42)		2.02 (0.52-7.76)		1.39 (0.52-3.74)		5.10 (0.69-37.76)		0.26 (0.04-1.48)		2.07 (0.64-6.75)		1.11 (0.32-3.85)		0.99 (0.35-2.85)			
BMI	0.99 (0.93-1.07)		1.00 (0.92-1.10)		1.05 (0.95-1.15)		1.03 (0.95-1.11)		1.05 (0.90-1.22)		1.00 (0.86-1.17)		0.99 (0.91-1.10)		0.86 (0.74-1.01)		1.07 (0.99-1.15)			
Dyslipidemia	1.45 (0.71-2.95)		0.58 (0.23-1.46)		0.68 (0.23-2.00)		0.88 (0.37-2.09)		0.84 (0.18-3.81)		0.31 (0.05-1.20)		0.53 (0.19-1.50)		0.62 (0.18-2.13)		1.77 (0.74-4.21)			
Diabetes	1.52 (0.37-6.34)		0.18 (0.02-2.08)		1.39 (0.19-10.25)		0.54 (0.09-3.37)		1.47 (0.08-25.51)		0.00		2.33 (0.29-18.54)		1.47 (0.11-19.71)		0.45 (0.09-2.34)			

aCL: anticardiolipin; β2-GP1: Beta2 glycoprotein 1; BMI: body mass index; C3: complement component 3; C4: complement component 4; LAC: lupus anticoagulant; MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; SLEDAI-2K: systemic lupus erythematosus disease activity index 2000; SDI: SLICC (systemic lupus international clinics) damage index; WMH: white matter hyperintensities.

† No association was found for ischemic lesions in the brainstem, large hemorrhages and sinus thrombosis.

‡ Pasquier scale ≥ 2.

* Reference Fazekas score ≤ 1.

a. P < 0.05; b. P < 0.001.

